Hydroxyapatite vs Fluoride Toothpaste: What the Evidence Actually Shows

Disclosure: this article contains affiliate links. If you buy through them, we may earn a commission at no extra cost to you. Prices were checked in September 2026.

Quick answer: Fluoride still has the larger, longer clinical evidence base for preventing cavities, decades of population-level data behind it. Hydroxyapatite has real head-to-head trials showing comparable remineralization in specific settings, but the total body of research is smaller and several of the strongest studies are funded by the toothpaste makers themselves. Neither the American Dental Association nor the FDA currently recognizes hydroxyapatite as a proven anticavity active ingredient in the United States.

What Do Head-to-Head Clinical Trials Actually Show?

The trials that exist mostly show hydroxyapatite performing on par with fluoride in specific, narrow comparisons, not a clear win across the board. Five studies matter most here, and knowing who paid for each one changes how much weight to give the result.

A 2019 in situ crossover trial out of the University of Texas Health San Antonio, led by Bennett Amaechi, put a toothpaste with 10% hydroxyapatite head to head against a 500 ppm amine fluoride toothpaste in 30 adults wearing intraoral appliances for two 14-day arms. Remineralization came out statistically even: 55.8% for the hydroxyapatite paste versus 56.9% for fluoride (p = 0.81), and lesion depth reduction was 27.1% versus 28.4% (p = 0.68). The paper reported no competing interests, which makes it one of the cleaner comparisons available (PMID 31839988).

A 2021 randomized trial in Scientific Reports followed 207 children for 336 days, comparing a microcrystalline hydroxyapatite toothpaste to a fluoride toothpaste. New caries lesions (ICDAS ≥ code 1) showed up in 72.7% of the hydroxyapatite group versus 74.2% of the fluoride group, a difference too small to call statistically significant. This trial was funded by Dr. Kurt Wolff GmbH & Co. KG, the German company that makes the hydroxyapatite toothpaste being tested (PMC7846568).

A follow-up 18-month double-blind trial in adults, published in Frontiers in Public Health in 2023, found 89.3% of the hydroxyapatite group and 87.4% of the fluoride group showed no increase in decayed, missing, or filled surfaces, again not significantly different. This one was also funded by Dr. Kurt Wolff GmbH & Co. KG, and three of the named authors are employees of that company, a conflict of interest that is disclosed in the paper itself, not hidden (Frontiers in Public Health, 2023).

An independent 2022 trial from the University of Pavia, with no external funding, tested biomimetic hydroxyapatite against 1,450 ppm fluoride toothpaste in 40 patients with white spot lesions and dentin sensitivity. Here hydroxyapatite actually pulled ahead on comfort: sensitivity scores dropped further and faster in the hydroxyapatite group over 90 days (PMC9317292).

A larger, more recent trial published in 2025 followed 610 children for 24 months, but it is worth reading the fine print: it compared a combination hydroxyapatite-plus-fluoride toothpaste (not fluoride-free) against a standard monofluoride paste. The combination group showed a statistically significant reduction in early enamel lesions (P < .01). It was funded by Curasept S.p.A., the manufacturer, alongside the University of Sassari; the paper states the manufacturer had no role in data analysis (PMID 39971658).

Zoom out to the systematic reviews and the picture holds: a 2021 meta-analysis of biomimetic hydroxyapatite trials found no statistically significant difference in caries risk reduction between hydroxyapatite and fluoride toothpaste across the pooled data (risk ratio 0.98, p = 0.61) (PMID 34925515). Non-inferior in trials that exist is a real result. It is not the same claim as “proven superior” or “equally studied,” and the honest reading of these five trials is that three of the five strongest ones were funded, at least in part, by the company selling the toothpaste being tested.

Does Hydroxyapatite Toothpaste Carry the ADA Seal of Acceptance?

No hydroxyapatite toothpaste currently carries the ADA Seal of Acceptance in the United States, because the Seal for anticavity claims requires fluoride. The American Dental Association’s own oral health guidance states that a toothpaste must contain fluoride to earn the Seal for cavity protection, a bar hydroxyapatite pastes cannot clear regardless of their other testing, because the Seal program is tied to the ingredient list, not just clinical outcomes (ADA, Toothpastes). The Seal itself has run since 1931 and requires independent lab or clinical testing against ADA Council on Scientific Affairs standards (ADA Seal of Acceptance). If the box in front of you has the ADA Seal for cavity prevention, it has fluoride in it. That is the fastest way to check in a store aisle.

What Does the FDA Actually Say About Hydroxyapatite?

The FDA’s OTC anticaries drug monograph lists exactly three approved active ingredients, and hydroxyapatite is not one of them. Under 21 CFR 355.10, the recognized anticaries active ingredients are sodium fluoride, sodium monofluorophosphate, and stannous fluoride, each with specific approved concentration ranges (21 CFR 355.10). That means a US hydroxyapatite toothpaste legally cannot print “fights cavities” or “anticavity” on the front of the tube, because that is a drug claim reserved for the ingredients listed in the monograph. It can print things like “remineralizes enamel” or “reduces sensitivity,” which are cosmetic-adjacent claims, not drug claims. This is a labeling and regulatory distinction, not a verdict on whether the ingredient works. Health Canada took a different position and approved a fluoride-free nano-hydroxyapatite toothpaste as anticavity back in 2015, which is one reason the same molecule gets a green light north of the border and a “cosmetic only” label south of it.

Why Is Hydroxyapatite Toothpaste Everywhere in Japan and Nowhere Near as Common in the US?

Hydroxyapatite toothpaste has been mainstream in Japan for over 40 years because the Japanese government formally recognized it as an anticavity agent in 1993, something the FDA still has not done. The ingredient’s commercial story starts with NASA: in the 1970s, the Japanese company Sangi licensed a NASA-developed process using brushite to grow synthetic hydroxyapatite, originally researched to help astronauts regrow minerals lost from bone and teeth in zero gravity (NASA Spinoff). Sangi launched the first hydroxyapatite toothpaste, Apadent, in Japan in 1980, followed by the now well-known Apagard line in 1985 (Sangi, Medical Hydroxyapatite). Europe caught up commercially around 2006, and the European Commission has since confirmed hydroxyapatite as safe for oral care use. Canada followed with regulatory approval in 2015. The US is the outlier, not because new safety data appeared, but because no manufacturer has taken hydroxyapatite through the FDA’s formal monograph review process for an OTC drug claim, and until one does, the ingredient stays in cosmetic-claim territory here.

Is Fluoride’s Evidence Base Actually Bigger, or Is That Just Marketing From Fluoride Brands?

Fluoride’s evidence base is genuinely, substantially larger, this is not spin from either side. Fluoride toothpaste has been studied in population-scale trials since the 1950s, with reviews covering tens of thousands of participants across decades, which is why every major dental and public health body, from the ADA to the World Health Organization, treats fluoride as the default anticavity standard. Hydroxyapatite’s clinical record is maybe 15 to 20 years of published RCTs, most of them small (30 to 600 participants), several funded by the two or three companies that make hydroxyapatite toothpaste. Presenting these two evidence bases as equivalent would be misleading. What the current trials support is a narrower, honest claim: in the short and medium-term trials run so far, hydroxyapatite performs comparably to fluoride on remineralization and new-lesion rates, and in a couple of independent trials, better on sensitivity. That is real and useful. It is not the same as “hydroxyapatite has caught up to fluoride.”

Who Should Actually Consider Switching to Hydroxyapatite?

Three groups get the clearest, most defensible case for trying hydroxyapatite toothpaste: people with diagnosed dentin hypersensitivity, parents of children under 6 who reliably swallow toothpaste, and people living in areas with fluorosis risk from high natural or added fluoride in drinking water. The sensitivity case has the best independent data behind it, the Butera 2022 trial (no industry funding) found faster relief on the Schiff Air Index and VAS pain scores with hydroxyapatite than with 1,450 ppm fluoride toothpaste over 90 days. For toddlers who swallow a pea-sized dab daily, hydroxyapatite is non-toxic if ingested in normal brushing amounts, whereas repeated fluoride ingestion during tooth development is the actual mechanism behind dental fluorosis, the white or brown mottling on permanent teeth the CDC has documented in children who consistently swallow fluoride toothpaste before age 6. If you already read ingredient labels the way you would for something like peptides in skincare, checking exactly what is going into your mouth or your kid’s mouth twice a day, hydroxyapatite is a legitimate, evidence-backed swap for these three groups specifically, not a blanket upgrade for everyone.

Who Should Not Drop Fluoride?

Anyone at elevated caries risk right now, orthodontic patients, and people with dry mouth from medication should stay on fluoride, full stop. If you have active cavities, a history of frequent new cavities, or no fluoridated tap water at home, fluoride’s decades of population data make it the safer default, not hydroxyapatite’s smaller, more industry-funded trial base. Braces wearers face higher plaque retention around brackets and a documented higher risk of white spot lesions during treatment, and every major orthodontic guideline still points to fluoride, sometimes a prescription-strength 5,000 ppm paste, as standard care. Dry mouth from antidepressants, antihistamines, blood pressure medication, or head and neck radiation reduces the saliva that buffers acid and remineralizes enamel, and dentists typically prescribe high-fluoride toothpaste for that, not hydroxyapatite. Switching away from fluoride in any of these three situations without talking to your dentist first is the actual risk here, not a minor tradeoff.

Two Products Worth Knowing If You Are Comparing Options

If you want to try a hydroxyapatite toothpaste, Boka’s Ela Mint formula is one of the more established nano-hydroxyapatite (n-Ha) options on the US market, priced at $11.62 for a one-time 4 oz tube or $9.30 with a 20% subscribe-and-save discount. It is fluoride-free, formulated with nano-hydroxyapatite, xylitol, coconut oil, and glycerin, with no SLS or parabens. Boka does not publish the exact percentage of nano-hydroxyapatite in the formula, the company’s own help center says the concentration is proprietary and was set by its formulators to balance remineralization benefits with safety, so treat that one number as company-disclosed policy rather than a published clinical figure (check current Boka pricing and formulas here).

Whitening is a separate chemistry from remineralization, hydroxyapatite polishes and remineralizes, it does not bleach. If whitening is actually what you are after, Opalescence is the more established, dentist-distributed option, with peroxide gel refills sold in 10%, 15%, 20%, 35%, and dental-office-only 45% concentrations. Its Opalescence Go Advanced 15% prefilled trays claim to whiten up to five shades, whitening strips run $29.00 for a 12-treatment pack, and its own Sensitivity Relief Whitening Toothpaste is $14.98. The brand markets itself as the top-selling professional whitening line with over 150 million smiles treated, which is a company claim worth noting as such rather than an independent statistic (see current Opalescence whitening options). Do not expect a hydroxyapatite toothpaste to whiten the way a peroxide system does, and do not expect a whitening system to remineralize enamel the way hydroxyapatite or fluoride can. They solve different problems.

Frequently Asked Questions

Is nano-hydroxyapatite toothpaste safe to swallow?

Yes, in the small amounts involved in normal brushing. Hydroxyapatite makes up roughly 97% of natural tooth enamel already, and unlike fluoride, there is no established toxic ingestion threshold tied to childhood tooth development, which is why it is often recommended for toddlers who swallow toothpaste.

Can I use hydroxyapatite and fluoride toothpaste together?

Some people alternate, using a fluoride toothpaste in the morning and a hydroxyapatite paste at night, though there is no dedicated RCT testing that specific alternating protocol against either paste used alone. If you are at high caries risk, talk to your dentist before dropping fluoride from any part of your routine.

Does hydroxyapatite toothpaste actually reverse cavities?

It can help remineralize very early, non-cavitated white spot lesions, the same limited claim that applies to fluoride. Neither ingredient reverses an actual cavity with a hole in it; once decay has cavitated, you need a dentist, not a different tube of toothpaste.

Why doesn’t the FDA allow “anticavity” claims on hydroxyapatite toothpaste?

Because the FDA’s OTC monograph for anticaries drugs, 21 CFR 355.10, lists only three approved active ingredients: sodium fluoride, sodium monofluorophosphate, and stannous fluoride. No manufacturer has taken hydroxyapatite through the FDA process required to add a new active ingredient to that list.

Is Boka’s toothpaste a good first hydroxyapatite toothpaste to try?

It is one of the more visible n-Ha options sold in the US, fluoride-free with xylitol and coconut oil in the formula, but the brand does not disclose its exact hydroxyapatite percentage. If you specifically want a published concentration figure to compare against the 10% used in the Amaechi 2019 trial, check the label or ask the brand directly before buying.

Is hydroxyapatite toothpaste better for sensitive teeth than fluoride?

The one independent, non-industry-funded trial that tested this directly found faster sensitivity relief with hydroxyapatite over 90 days compared to 1,450 ppm fluoride toothpaste. That is a genuine finding, though it comes from a single 40-patient trial, not a large body of replicated research.

Bottom Line

Match the product to the actual problem: pick a hydroxyapatite paste like Boka’s fluoride-free n-Ha toothpaste if sensitivity or toddler swallowing is the concern, keep fluoride if you are at real cavity risk, and reach for a dedicated system like Opalescence’s peroxide whitening line only when the goal is shade change, not remineralization. None of these three jobs substitute for the other two.

This article is for general information only and does not replace advice from a licensed dentist. Talk to your dentist about your specific cavity risk, fluorosis history, and any medications affecting your saliva before changing your toothpaste.